ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,771Medicare Part D Prescriptions Filled, Including Refills

Rank: 4 out of 224

$467K Total Retail Price of All Prescriptions

Rank: 17 out of 224

598 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
47% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Vermont
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 598 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

15% of this provider’s 598 patients filled at least one prescription for a schedule three drug, compared to an average of 7%.

Risky Drugs to Seniors

2% of this provider’s 8,040 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

18% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$43 was the average price of a prescription from this provider, compared to $63 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Vermont
LISINOPRIL 689 533 1 2
LEVOTHYROXINE SODIUM 579 476 2 4
SIMVASTATIN 448 369 3 1
OMEPRAZOLE 400 313 4 3
METFORMIN HCL 391 323 5 9
HYDROCODONE-ACETAMINOPHEN 324 209 S3 6 12
AMLODIPINE BESYLATE 223 192 7 8
LOVASTATIN 222 199 8 33
GABAPENTIN 189 149 9 14
HYDROCHLOROTHIAZIDE 163 140 10 6
ZOLPIDEM TARTRATE 153 100 11 22
METOPROLOL TARTRATE 150 133 12 7
LISINOPRIL-HYDROCHLOROTHIAZIDE 149 122 13 35
ATENOLOL 145 115 14 13
CITALOPRAM HBR 134 119 15 15
TRAMADOL HCL 125 67 16 18
FUROSEMIDE 124 96 17 5
LOSARTAN POTASSIUM 115 82 18 19
FENOFIBRATE 114 69 19 123
OXYCODONE HCL 114 30 S2 19 25
FLUTICASONE PROPIONATE 108 88 21 45
ATORVASTATIN CALCIUM 108 80 21 16
SERTRALINE HCL 106 67 23 17
IBUPROFEN 104 73 24 51
DONEPEZIL HCL 102 102 25 36
CRESTOR 97 65 26 38
PROAIR HFA 96 72 27 26
METOPROLOL SUCCINATE 95 87 28 11
PAROXETINE HCL 89 52 29 52
ALENDRONATE SODIUM 87 75 30 39
GLIPIZIDE 86 74 31 69
FLUOXETINE HCL 85 20 32 37
ENDOCET 82 24 S2 33 116
MELOXICAM 78 59 34 72
RANITIDINE HCL 77 55 35 29
POTASSIUM CHLORIDE 75 62 36 24
GLYBURIDE 75 68 R 36 61
AMITRIPTYLINE HCL 74 60 R 38 78
OXYCODONE-ACETAMINOPHEN 74 37 S2 38 41
TRIAMTERENE-HCTZ 74 71 38 90
CIPROFLOXACIN HCL 69 50 41 95
LANTUS 68 51 42 43
TRAZODONE HCL 66 51 43 20
NAMENDA 66 66 43 65
PRAVASTATIN SODIUM 65 52 45 21
GLIPIZIDE ER 65 60 45 152
DOXAZOSIN MESYLATE 61 61 47 119
JANUVIA 59 40 48 75
OXYBUTYNIN CHLORIDE 58 46 49 110
VERAPAMIL ER 58 57 49 79
AMOXICILLIN 53 33 51 167
TRIAMCINOLONE ACETONIDE 50 26 52 93
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.